Melphalan‐Induced Supraventricular Tachycardia: Incidence and Risk Factors
Authors:
Open Access
- 27 April 2011
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 34 (6) , 356-359
Abstract
Background: Cardiotoxicity of aggressive chemotherapeutic regimens includes cardiomyopathy and arrhythmias. Although cardiomyopathy is a well‐recognized entity, arrhythmias are poorly studied.Hypothesis: Certain chemotherapeutic regimes are associated with supraventricular arrhythmias, particularly atrial fibrillation.Methods: We retrospectively reviewed the data on patients who received hematopoietic stem cell transplant (bone marrow transplant; BMT) from 1998 to 2005 and developed supraventricular tachycardia (SVT) during the same hospital admission. The Fisher χ2 test and the Student t test were used for comparison of categorical and continuous variables, respectively.Results: During the period of 1998–2005, there were 1221 BMTs, 62 (5.1%) of which were complicated by SVT. Melphalan‐based regimens demonstrated a significantly higher rate of SVT than any other chemotherapy. Out of 438 patients who received melphalan, 48 (11%) developed atrial fibrillation (n = 35) or SVT (n = 13) during the same hospital admission, and 390 did not. Patients with SVT were older, had higher baseline creatinine, larger size of the left atrium, and more cardiac comorbidities. Incidence of SVT was associated with greater length of stay (24.9 ± 8.9 d vs 19.6 ± 5.8 days, P<0.0001), even after adjustment for comorbidities.Conclusions: Supraventricular tachycardia, mostly atrial fibrillation, complicates about 5% of chemotherapeutic treatments used with BMT. Melphalan is the most arrhythmogenic agent, and is associated with SVT in 11% of patients. Development of SVT results in about a 4‐day increase in the length of hospital stay. © 2011 Wiley Periodicals, Inc.The authors have no funding, financial relationships, or conflicts of interest to disclose.Keywords
This publication has 12 references indexed in Scilit:
- Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)American Heart Journal, 2010
- Impaired Kidney Function and Atrial Fibrillation in Elderly SubjectsJournal of Cardiac Failure, 2010
- Introducing a new entity: chemotherapy-induced arrhythmiaEP Europace, 2009
- Relation of Atrial Fibrillation to Glomerular Filtration RateThe American Journal of Cardiology, 2008
- Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and olderLeukemia & Lymphoma, 2005
- Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I studyTransplantation and Cellular Therapy, 2004
- Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphoblastic leukaemiaBone Marrow Transplantation, 2000
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and overBone Marrow Transplantation, 2000
- Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myelomaBone Marrow Transplantation, 1999
- Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cellsBone Marrow Transplantation, 1998